Composition and distribution of lipoproteins after evolocumab in familial dysbetalipoproteinemia. A randomized controlled trial

Britt E. Heidemann, A. David Marais, Monique T. Mulder, Frank L.J. Visseren*, Jeanine E. Roeters van Lennep, Erik S.G. Stroes, Niels P. Riksen, Leonie C. van Vark – van der Zee, Dee M. Blackhurst, Charlotte Koopal

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

15 Downloads (Pure)

Abstract

Background: Proprotein convertase subtilisin kexin type 9 (PCSK9) monoclonal antibodies (mAbs) reduce fasting and post fat load cholesterol in non-HDL and intermediate density lipoprotein (IDL) in familial dysbetalipoproteinemia (FD). However, the effect of PCSK9 mAbs on the distribution and composition of atherogenic lipoproteins in patients with FD is unknown. Objective: To evaluate the effect of the PCSK9 mAb evolocumab added to standard lipid-lowering therapy in patients with FD on fasting and post fat load lipoprotein distribution and composition. Methods: Randomized placebo-controlled double-blind crossover trial comparing evolocumab (140 mg subcutaneous every 2 weeks) with placebo during two 12-week treatment periods. Patients received an oral fat load at the start and end of each treatment period. Apolipoproteins (apo) were measured with ultracentrifugation, gradient gel electrophoresis, retinyl palmitate and SDS-PAGE. Results: PCSK9 mAbs significantly reduced particle number of all atherogenic lipoproteins, with a stronger effect on smaller lipoproteins than on larger lipoproteins (e.g. IDL-apoB 49%, 95%confidence interval (CI) 41–59 and very low-density lipoprotein (VLDL)-apoB 33%, 95%CI 16-50). Furthermore, PCSK9 mAbs lowered cholesterol more than triglyceride (TG) in VLDL, IDL and low-density lipoprotein (LDL) (e.g. VLDL-C 48%, 95%CI 29–63%; and VLDL-TG 20%, 95%CI 6.3–41%). PCSK9 mAbs did not affect the post fat load response of chylomicrons. Conclusion: PCSK9 mAbs added to standard lipid-lowering therapy in FD patients significantly reduced lipoprotein particle number, in particular the smaller and more cholesterol-rich lipoproteins (i.e. IDL and LDL). PCSK9 mAbs did not affect chylomicron metabolism. It seems likely that the observed effects are achieved by increased hepatic lipoprotein clearance, but the specific working mechanism of PCSK9 mAbs in FD patients remains to be elucidated.

Original languageEnglish
Pages (from-to)666-676
Number of pages11
JournalJournal of Clinical Lipidology
Volume17
Issue number5
DOIs
Publication statusPublished - Sept 2023

Keywords

  • Apolipoprotein B
  • Clinical trial
  • Familial dysbetalipoproteinemia
  • Fasting
  • Lipoproteins
  • PCSK9 monoclonal antibodies
  • Postprandial
  • Type III hyperlipoproteinemia

Fingerprint

Dive into the research topics of 'Composition and distribution of lipoproteins after evolocumab in familial dysbetalipoproteinemia. A randomized controlled trial'. Together they form a unique fingerprint.

Cite this